doi: 10.1158/0008-5472.CAN-15-2328 81 GreeneCJSharmaNJFioricaPNForresterESmithGJGrossKWet al
The project co-led by Timothy Marlowe, PhD, associate professor in the Department of Internal Medicine , the U of A Cancer Center and the College of Pharmacy, Michael Fallon, MD, FACP , executive director for Clinical Research and chair of the Department of Internal Medicine, and Hyo Jin Park, PhD, assistant research scientist in the Department of Internal Medicine targets the connection between focal adhesion kinase (FAK) and paxillin, two proteins that become hyperactive during fibrosis and fuel the buildup of scar tissue in the liver
When removing a vial from frozen storage, allow it to reach room temperature before opening to prevent condensation from introducing moisture into the vial
Common research dose 300-500 mcg/day in research planning context, drawn from the dose range used across the published Phase 1/2 trials
309 It includes a series of diseases, such as simple fatty liver (hepatic steatosis), non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma
GHK-Cu Copper Peptides 1% Copper tripeptide-1
